$VNDA

12 Health Care Stocks Moving In Monday's Intraday Session

This article lists 12 healthcare stocks that experienced significant movement during Monday's intraday trading session. It highlights several gainers, including Arcellx (NASDAQ: ACLX) and Vanda Pharmaceuticals (NASDAQ: VNDA), and several decliners such as Gossamer Bio (NASDAQ: GOSS) and 20/20 Biolabs (NASDAQ: AIDX), along with their respective percentage changes and market caps.

Original reporting
Benzinga · Benzinga Insights, Benzinga Staff Writer
Published Feb 23, 2026, 5:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 23, 2026, 5:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
12 Health Care Stocks Moving In Monday's Intraday Session — source image
Decision brief

The 30-second read

$VNDANeutralMed
01

Why it matters

Short-term trading opportunities exist based on intraday momentum; however, fundamental factors are not discussed.

02

Market read

The stocks mentioned are active in the healthcare sector with recent intraday volatility, providing potential trading opportunities for short-term traders.

03

What to watch

Broader market trends, upcoming earnings reports, and sector news could significantly influence stock movements beyond current data.

Timing: Immediate; intraday movements suggest short-term trading opportunities.

Background

The article reports on intraday movements of 12 healthcare stocks, highlighting both gainers and decliners.

Company-level read

Ticker impact

$VNDANeutralMedium confidence
Context

Moderate relevance; highlighted as a gainer but with less explicit sentiment data.

Expected impact

Potential slight upward movement of 1-2% if current trend persists.

Evidence & confidence

Limited sentiment data and moderate relevance imply cautious optimism; traders should monitor upcoming news for confirmation.

$GOSSBearishMedium confidence
Context

Low relevance; mentioned as a decliner with no specific sentiment data.

Expected impact

Possible further decline of 2-4% if negative momentum continues.

Evidence & confidence

Recent decline suggests bearish sentiment; risk of continued downward movement exists.

$AIDXBearishLow confidence
Context

Low relevance; minor mention as a decliner without detailed sentiment.

Expected impact

Potential for continued decline, but with low confidence due to limited data.

Evidence & confidence

Insufficient sentiment and technical data; traders should await further confirmation.

Market effects

Healthcare sector showing active trading, possibly indicating sector-wide volatility.

Limited; focus remains on specific stocks without broader regional implications.

Low; news pertains mainly to individual stocks within the US healthcare sector.

Counterpoint

The recent intraday gains may be temporary; overbought conditions could lead to reversals.

Key entities

  • Arcellx

    A biotechnology company focused on cell therapies.

  • Vanda Pharmaceuticals

    A biopharmaceutical company developing treatments for central nervous system disorders.

  • Gossamer Bio

    A biotechnology company developing therapies for various diseases.

  • 20/20 Biolabs

    A biotech firm engaged in developing novel therapeutics.

Related articles

$VNDAMed

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals said the FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in Q1 2026, and it plans a commercial launch in the second half of 2026. U.S. data exclusivity runs to Feb 20, 2031, with patents to May 31, 2044. Vanda reported Q2 net product sales of $50.5M and expects Phase III readouts before year-end 2026.

$VNDAMedAI 8/10

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

Vanda Pharmaceuticals (VNDA) said its motion sickness drug Nereus is now commercially available across the U.S., after FDA approval in December for preventing vomiting in adults. Vanda estimates motion sickness affects 25% to 30% of adults. Nereus is offered via direct-to-consumer and retail pharmacies, with a $85 cash-pay dose versus a $255 list price. VNDA shares rose about 4% after hours.

$GOSSMedAI 8/10

Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.